Graves' ophthalmopathy

Fang Ping Kung, Hao-Chang Hung, Horng-Yih Ou, Ta Jen Wu

Research output: Contribution to journalReview article

Abstract

Graves' ophthalmopathy (GO) is the most common orbital disease in adults and develops in 25% to 50% of patients with Graves' disease (GD). Although thyroid manifestations of GD can be effectively managed, the optimal treatment of GO has remained challenging. The natural history of GO is variable. Patients should be treated according to the severity and activity of their eye disease. Treatment should include control of thyroid function, relief of symptom and reduction of inflammation in the periorbital tissues. Smoker should be educated to quit smoking aggressively. Most patients have mild disease and do not have progression during follow-up. Anti-thyroid drugs and thyroidectomy do not have a negative influence on the course of GO. However, there is increasing evidence that radioiodine therapy can cause the development or worsening of GO. Glucocorticoids(GCs) are the preferred first-line treatment for moderate and severe GO. IV GCs is more effective than oral GCs. Radiation and surgical decompression can also be used in selected patients.

Original languageEnglish
Pages (from-to)9-20
Number of pages12
JournalJournal of Internal Medicine of Taiwan
Volume23
Issue number1
Publication statusPublished - 2012 Feb 1

Fingerprint

Graves Ophthalmopathy
Glucocorticoids
Thyroid Gland
Graves Disease
Orbital Diseases
Surgical Decompression
Eye Diseases
Thyroidectomy
Therapeutics
Smoking
Radiation
Inflammation
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Kung, Fang Ping ; Hung, Hao-Chang ; Ou, Horng-Yih ; Wu, Ta Jen. / Graves' ophthalmopathy. In: Journal of Internal Medicine of Taiwan. 2012 ; Vol. 23, No. 1. pp. 9-20.
@article{23007082172449ac93c75561e6600946,
title = "Graves' ophthalmopathy",
abstract = "Graves' ophthalmopathy (GO) is the most common orbital disease in adults and develops in 25{\%} to 50{\%} of patients with Graves' disease (GD). Although thyroid manifestations of GD can be effectively managed, the optimal treatment of GO has remained challenging. The natural history of GO is variable. Patients should be treated according to the severity and activity of their eye disease. Treatment should include control of thyroid function, relief of symptom and reduction of inflammation in the periorbital tissues. Smoker should be educated to quit smoking aggressively. Most patients have mild disease and do not have progression during follow-up. Anti-thyroid drugs and thyroidectomy do not have a negative influence on the course of GO. However, there is increasing evidence that radioiodine therapy can cause the development or worsening of GO. Glucocorticoids(GCs) are the preferred first-line treatment for moderate and severe GO. IV GCs is more effective than oral GCs. Radiation and surgical decompression can also be used in selected patients.",
author = "Kung, {Fang Ping} and Hao-Chang Hung and Horng-Yih Ou and Wu, {Ta Jen}",
year = "2012",
month = "2",
day = "1",
language = "English",
volume = "23",
pages = "9--20",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "Society of Internal Medicine of Taiwan",
number = "1",

}

Kung, FP, Hung, H-C, Ou, H-Y & Wu, TJ 2012, 'Graves' ophthalmopathy', Journal of Internal Medicine of Taiwan, vol. 23, no. 1, pp. 9-20.

Graves' ophthalmopathy. / Kung, Fang Ping; Hung, Hao-Chang; Ou, Horng-Yih; Wu, Ta Jen.

In: Journal of Internal Medicine of Taiwan, Vol. 23, No. 1, 01.02.2012, p. 9-20.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Graves' ophthalmopathy

AU - Kung, Fang Ping

AU - Hung, Hao-Chang

AU - Ou, Horng-Yih

AU - Wu, Ta Jen

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Graves' ophthalmopathy (GO) is the most common orbital disease in adults and develops in 25% to 50% of patients with Graves' disease (GD). Although thyroid manifestations of GD can be effectively managed, the optimal treatment of GO has remained challenging. The natural history of GO is variable. Patients should be treated according to the severity and activity of their eye disease. Treatment should include control of thyroid function, relief of symptom and reduction of inflammation in the periorbital tissues. Smoker should be educated to quit smoking aggressively. Most patients have mild disease and do not have progression during follow-up. Anti-thyroid drugs and thyroidectomy do not have a negative influence on the course of GO. However, there is increasing evidence that radioiodine therapy can cause the development or worsening of GO. Glucocorticoids(GCs) are the preferred first-line treatment for moderate and severe GO. IV GCs is more effective than oral GCs. Radiation and surgical decompression can also be used in selected patients.

AB - Graves' ophthalmopathy (GO) is the most common orbital disease in adults and develops in 25% to 50% of patients with Graves' disease (GD). Although thyroid manifestations of GD can be effectively managed, the optimal treatment of GO has remained challenging. The natural history of GO is variable. Patients should be treated according to the severity and activity of their eye disease. Treatment should include control of thyroid function, relief of symptom and reduction of inflammation in the periorbital tissues. Smoker should be educated to quit smoking aggressively. Most patients have mild disease and do not have progression during follow-up. Anti-thyroid drugs and thyroidectomy do not have a negative influence on the course of GO. However, there is increasing evidence that radioiodine therapy can cause the development or worsening of GO. Glucocorticoids(GCs) are the preferred first-line treatment for moderate and severe GO. IV GCs is more effective than oral GCs. Radiation and surgical decompression can also be used in selected patients.

UR - http://www.scopus.com/inward/record.url?scp=84859179137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859179137&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84859179137

VL - 23

SP - 9

EP - 20

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 1

ER -